Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib in advanced liposarcoma
NCT02571829Phase 2Unknown
- Sponsor
- Hadassah Medical Organization
- Start
- May 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ribociclib in Liposarcoma and dedifferentiated liposarcoma (DDL), sponsored by Hadassah Medical Organization. Primary endpoint: Response to therapy as evaluated by RECIST 1.1 and Choi at 36 months. Status: unknown.
02
Drugs
ribociclib
03
Conditions
Liposarcomadedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on NCT02571829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02571829.